Neuland makes the active ingredient inside other companies' medicines, and does it twice over. One arm sells generic APIs it developed itself — over a hundred, some mature and price-fought, some complex enough to have almost no rivals. The other makes molecules exclusively for innovators, to the innovator's process, from grams for trials to tonnes for launch. That second arm has quietly taken the company over: 45% of revenue a year ago, 68% in the June quarter. On quality the answer is eighteen cleared US FDA inspections and eighty countries served. On results it is blunter — ₹16 crore of profit in FY19, ₹364 crore last year, and a share count that has not moved in five years.
Yes, and one number explains how this business actually works. Ninety-nine contract projects were live in the June quarter against 98 a year earlier, and nineteen were in commercial supply in both years. Revenue from that segment went from ₹133 crore to ₹438 crore. Almost nothing new was won — the existing orders simply got much bigger. Management's own illustration is a single molecule worth ₹200 crore in a year the customer is launching and ₹50 crore in a year it is not. Eighteen cleared US FDA inspections buy the seat at the table. The customer's launch calendar decides the year.
No — but watch what the debt is buying. Borrowings nearly doubled last year to ₹301 crore, against ₹355 crore of cash, so there is still more cash than debt and a debt-to-equity of 0.16. The figure that matters is not on the balance sheet: ₹1,460 crore of capital projects approved over thirteen quarters, ₹870 crore of it spent. Neuland is committing about four years of profit to new plants and paying for most of it out of what it earns.
Both, and margins did the heavier lifting. Revenue grew 37% last year and profit 40%, but the operating margin went from 22.4% to 28.7% — Neuland earned more per rupee of sales, not just more rupees. The June quarter pushed that to 34.7%, against 11.8% a year before. The same factories, the same people, produced those two numbers twelve months apart. That is what operating leverage looks like, in both directions.
Fast, though the shape matters more than the rate. Revenue rose 37% last year to ₹2,023 crore and profit 40% to ₹364 crore — and the year before that, both fell. The June quarter did not grow so much as double: ₹642 crore against ₹293 crore, with profit going from ₹14 crore to ₹148 crore. Three-year growth of 19% a year is the number worth keeping. The quarterly line is a saw, not a slope.
Entirely on its own; there is not an acquisition in the accounts. It spent ₹423 crore on investment last year and lifted the plant base 23%, ₹955 crore to ₹1,177 crore. The line that matters more is work in progress, which went from ₹48 crore to ₹211 crore — a peptide facility, new R&D, and ₹196 crore newly approved for Unit-1. Of ₹1,460 crore sanctioned over thirteen quarters, ₹870 crore is spent. Neuland is rebuilding itself while running.
Improving, and the reason is worth knowing. Operating margin rose from 22.4% to 28.7%. Gross margin actually fell, 60.8% to 59.3% — so the gain did not come from better prices or cheaper inputs. It came from volume passing over a fixed cost base. That is the good kind of margin gain and the fragile kind: it reverses the moment volume does. Net margin, after depreciation and interest on the new plants, barely moved — 17.6% to 18.0%.
Yes, and better than most of its neighbours. Return on capital was 26.6%, up from 23.2% — against Divi's 21.5%, Laurus 18.0% and Piramal 1.2%. Only Anthem earns more, at 29.6%. Return on equity is lower at 19.4%, and the gap is deliberate: ₹211 crore of plant is still under construction and earning nothing. The real test is what 26.6% becomes once ₹1,460 crore of new capacity has to pay for itself.
Yes, with one thing to watch. It turned ₹364 crore of profit into ₹347 crore of operating cash, and across three years cash and profit have matched almost exactly — a ratio of 1.00, which is as clean as this measure gets. The strain is collection: customers took 98 days to pay against 78, and receivables went from ₹316 crore to ₹541 crore. Management says that has since reversed, to 84 days of working capital in the June quarter from 137 in March. Worth checking next quarter rather than taking on trust.
A family company that has just handed over inside the family. Dr. Davuluri Rama Mohan Rao, who founded Neuland in 1984, is Executive Chairman. His sons hold the other two senior seats: Sucheth Rao, chief executive from 2009 until March 2026, is now Executive Vice-Chairman, and Saharsh Rao took over as CEO and Managing Director. Three of eight board seats; the other five are independent. What separates Neuland from its peers is how little of it the family owns — 32.6%, against 51.9% at Divi's and 71.4% at Anthem.
Nothing that threatens anything. Disputed claims come to about ₹13 crore against ₹364 crore of profit: ₹7.5 crore of income tax, a ₹4.5 crore electricity surcharge that appeared this year, ₹1.1 crore of GST. Two small land parcels at Bonthapally are subject to a revenue department notice claiming they were assigned land, and some labour cases in Telangana are unquantified. The auditors, M S K A & Associates — the Indian member firm of BDO — signed without qualification and reported no fraud, and the company states no related-party transaction fell outside arm's length.
Neuland sits in the same room as Divi's, Laurus and Syngene and is much the smallest of them. What separates it is what it refuses to do: it has no finished-dosage business, so an innovator handing over a molecule is not handing it to a future competitor. Forty years of API chemistry, three US FDA plants, and a deliberate decision not to go downstream.
In contract manufacturing: Divi's Laboratories, worth about seven times as much, along with Laurus Labs, Syngene International, Sai Life Sciences and Piramal Pharma. In generic APIs the field is far wider and includes the API arms of most large Indian pharma companies. Neuland's answer to both is narrowness — a hundred APIs it developed itself, chemistry it has been doing for four decades, and nothing downstream to make a customer nervous.
In its favour: contract revenue that tripled in a year to ₹438 crore, a June-quarter operating margin of 34.7%, ₹1,460 crore of capacity being built, a new sterile-API collaboration with Gland Pharma, covered here, and a model that does not compete with its own customers. Against it: nineteen commercial projects carry that segment, so losing one would show immediately; the same concentration is why a June quarter can go from an 11.8% margin to 34.7%; and at ₹22,855 on 7 August 2026 the share was priced at 80 times earnings.
Growing, in bursts, and Neuland's own record makes the case better than any industry forecast could. Revenue fell 5% in FY25 and rose 37% in FY26, with nothing much changing about the industry in between. What moved was a handful of customers' decisions: the money reaching a contract manufacturer starts as someone else's research budget and ends as their launch date, and neither arrives on a schedule you can plan around. The demand underneath is durable. The particular twelve months you happen to own it for are not.
Neuland is priced as though the last two years are the new normal. The share has nearly doubled and trades at 80 times earnings — above Divi's and Anthem, below Laurus, and it is the smallest of the four. Domestic funds have been buying steadily; small shareholders have been selling into them.
Expensive, and priced alongside the best of its peers rather than at a discount for being the smallest. At ₹22,855 on 7 August 2026 the share was at 80 times earnings, 15.6 times book value and 14.5 times sales, on FY26 earnings of ₹284.38 a share and a market value of ₹29,254 crore. Divi's was at 86 times, Anthem 80, Laurus 112, Syngene 55. Set against three-year profit growth of 31% a year that is 2.6 times growth, the least stretched figure on this page. What the price is really asking is whether 37% revenue growth was a step change or a good year.
Institutions have bought in every single quarter for a year and a half. Their holding went 33.08%, 33.26%, 34.14%, 35.61%, 36.30%, 37.59% — six filings, six increases, with Indian funds doing most of it as they rose from 10.97% to 16.51%. Small shareholders funded it, falling from 33.84% to 29.79%. The founders sold nothing: 32.68% to 32.62% over the same stretch, which is rounding rather than selling. A share that nearly doubled while the register moved this steadily in one direction is not being pushed around by a crowd.
Yes, and two of them are individuals. Malabar India Fund is the largest outside holder at 5.42%, and has been quietly trimming — 5.76% eighteen months ago. Mukul Mahavir Agrawal, one of India's better-known private investors, holds 3.12% and has not moved it by a single basis point across all six quarters on file; Kedia Securities has sat at exactly 1.01% for just as long. Siddharth Iyer holds 1.67%. Among the funds: ICICI Prudential Balanced Advantage 2.19%, Mahindra Manulife's ELSS fund 1.93%, HSBC Small Cap 1.55%, Bajaj Finserv Flexi Cap and an HDFC index fund at 1.28% each, Jupiter India 1.19%. Ten holders above 1% is a crowded register for a company this size.
Paying dividends, borrowing a little, and leaving the share count alone. The dividend nearly tripled, ₹12.09 to ₹34.27 a share, and is still only 12% of profit — the rest is going into plants. Borrowings rose ₹144 crore. No buyback. The share count has not moved in five years, over which profit more than quadrupled, so existing owners kept all of it.
Loading…